Approach to the Management of Idiopathic Hirsutism

Total Page:16

File Type:pdf, Size:1020Kb

Approach to the Management of Idiopathic Hirsutism RxFiles Approach to the management of idiopathic hirsutism Milena Markovski MD CCFP Jill Hall ACPR Margaret Jin PharmD CDE CGP Tessa Laubscher MB ChB CCFP FCFP Loren Regier Case description • idiopathic hyperandrogenism—clinical and biochem- A 25-year-old white woman, A.G., presents to a ical hyperandrogenism but regular ovulatory cycles of family practice clinic seeking a levonorgestrel intra- normal length and normal ovary morphology; uterine device (IUD) for contraception. She has only • idiopathic hirsutism—hirsutism with normal andro- used condoms in the past, but A.G. recently became gen concentrations, ovulatory cycles, and ovary engaged and wants to avoid pregnancy for several morphology; more years while she completes her master’s degree. • nonclassic congenital adrenal hyperplasia; Her medical history is noncontributory; she has no • androgen-secreting tumours; and known allergies, is a non-smoker, uses no illicit • iatrogenic excess androgen. drugs, and has minimal alcohol intake. She takes a Hirsutism should be investigated and treated, not only daily multivitamin. to determine the underlying cause, but also because it Further history reveals that since puberty A.G. can negatively affect women’s psychological well-being. has experienced increased growth of facial hair. It A detailed history and physical examination are has caused considerable embarrassment for her, and most valuable when determining the cause of hirsutism. she is reluctant to discuss this issue with her physi- Methods for evaluation can be subjective and objective. cian. She also has mild acne, but has not tried any Visually scoring the body and facial terminal hair growth prescription therapies. She has heard from friends in specified body areas using the Ferriman-Gallwey that contraceptive pills cause increased growth score is more convenient and less expensive than of facial hair, and for this reason she has never more objective scoring with photographic evaluations, used any birth control medication. She has regular microscopic measurements, and weighing of shaved or monthly menses. plucked hair. The Ferriman-Gallwey tool scores 9 of the 11 androgen-sensitive hair growth areas on a scale of Examination 0 to 4 (for a maximum score of 36). A score of 8 to 15 Examination findings reveal that A.G. is a pleas- is considered mild hirsutism; a score above 15 is con- ant woman with appropriate affect. Measurements of sidered moderate to severe hirsutism.1 her vital signs are normal, with a blood pressure of Determination of serum androgen levels should be 110/84 mm Hg. Her body mass index is 26.8 kg/m2. the first step for establishing the cause of hirsutism. There is a moderate increase of dark facial hair in the Androgen contributes to the growth of sexual hair in chin area and on the upper lip. Her abdomen is soft and both sexes, as well as to the growth of facial and trunk nontender. She declines a pelvic examination because hair in women with hirsutism. The androgens found in she is menstruating. female serum include DHEA-S, DHEA, androstenedione, The patient is counseled about the causes of hirsut- testosterone, and dihydrotestosterone. The most active ism and agrees to further investigation. She is given a androgen, dihydrotestosterone, has low serum levels requisition for measurement of complete blood count; because it is synthesized in androgen target tissues. thyroid-stimulating hormone, fasting plasma glucose, For this reason, measurable circulating androgen levels and lipid levels; a renal panel; and free testosterone, might not reflect androgen activity in the hair follicles of luteinizing hormone, follicle-stimulating hormone, and women with hirsutism. Serum levels of DHEA-S and free dehydroepiandrosterone sulfate (DHEA-S) levels. A pel- testosterone are the most sensitive measurements of vic ultrasound is ordered as well, and A.G. is asked to androgen excess and are considered tumour markers.2,3 follow up in 2 weeks, at which time a suitable contra- If PCOS is suspected, a metabolic evaluation (meas- ceptive method will be discussed. urement of plasma glucose levels, waist circumference and body mass index, complete lipid profile, and blood Diagnostic approach pressure) is necessary to evaluate the patient’s risk of Androgen-excess disorders to consider in A.G.’s case metabolic and cardiovascular dysfunction. A common include the following: finding in PCOS is an increased luteinizing hormone to fol- • polycystic ovary syndrome (PCOS)—clinical or bio- licle-stimulating hormone ratio (> 2.5). Ultrasound might chemical hyperandrogenism in addition to ovarian aid in diagnosing PCOS, as well as nonclassic congenital dysfunction or polycystic ovary morphology; adrenal hyperplasia or androgen-secreting tumours. VOL 58: FEBRUARY • FÉVRIER 2012 | Canadian Family Physician • Le Médecin de famille canadien 173 RxFiles Management of hirsutism which the drug cannot be stopped, cosmetic measures An approach to treatment of hirsutism is outlined in might be of value to conceal or remove hair. Figure 1.1,2,4 Nonpharmacologic intervention. Targeted coun- Rule out potential drug-related causes. Drugs seling about self-image plays an important role in that can cause excessive hair growth (hirsutism or the treatment of hirsutism. Lifestyle modifications, hypertrichosis) include acetazolamide, anabolic ste- such as physical exercise and dietary advice, can roids (eg, danazol, nandrolone, stanozolol), andro- be recommended. Such modifications might be less genic progestogens or oral contraceptive pills (OCPs) effective for idiopathic hirsutism than for hirsutism containing progestogen (eg, norethindrone and caused by PCOS; however, they might also be worth- levonorgestrel found in first- and second-genera- while for cardiovascular protection.2 Cosmetic mea- tion OCPs), cyclosporine, diazoxide, glucocorticoids, sures, such as bleaching, plucking, shaving, waxing, drugs containing heavy metals, minoxidil, penicilla- chemical treatment, electrolysis, laser hair removal, mine, phenytoin, tamoxifen, and thyroxine.5,6 Drug- and intense pulsed light are usually effective in con- induced excessive hair growth is reversible upon trolling mild hirsutism, especially when terminal hair discontinuation of the offending agent. In cases in localizes in exposed areas such as the face. Figure 1. Management of idiopathic hirsutism HIRSUTISM Cosmetic procedures are a cornerstone of care; examples include laser surgery, Consider any drug-related causes shaving, plucking, bleaching, waxing, Initiate lifestyle modications chemical treatment, intense pulsed light, Consider cosmetic procedure options and electrolysis Seeking fertility Not seeking fertility Delay drug treatment Moderate to severe until delivery Mild hirsutism hirsutism Contraindication 1. Topical eornithine (8-wk OCP containing to OCP trial) (monotherapy or as an • Cyproterone adjunct to any hair removal • Drospirenone technique) • Neutral progestin (desogestral, norgestimate) 2. OCP containing Antiandrogen (with secure • Cyproterone PLUS antiandrogen contraception) • Drospirenone • Spironolactone • Spironolactone • Neutral progestin • Finasteride or cyproterone • Finasteride (desogestrel, norgestimate) • Cyproterone acetate • Flutamide Unsatisfactory result (at 6-12 mo) Metformin, while benecial in PCOS, is not effective for idiopathic hirsutism • Add oral agent to topical eflornithine • Add spironolactone, finasteride, or cyproterone to OCP OCP—oral contraceptive pill, PCOS—polycystic ovary syndrome. Adapted from Hirsutism.com,1 Escobar-Morreale et al,2 and Harrison et al.4 174 Canadian Family Physician • Le Médecin de famille canadien | VOL 58: FEBRUARY • FÉVRIER 2012 RxFiles Table 1. Medications used for idiopathic hirsutism1-8: Medications listed are contraindicated in pregnancy and require use of appropriate contraception. CLASS AND INGREDIENTS ROLE IN THERAPY EFFICACY DOSE (COST/30 D) • Eflornithine 13.9% • Monotherapy for mild cases of • Improvement noted at ≥ 8 wk; Topical; apply twice cream (Vaniqa) facial hirsutism or as adjunct to effect reverses 8 wk after daily, at least other therapies (complements discontinuation12-14 8 h apart antiandrogen, laser, or IPL • Used alone, treatment is successful ($64 per 30-g tube; CCI therapy) about 30% of the time (slows rate lasts about 3-5 mo for • Considered first-line in of hair growth); variable cosmetic upper lip and postmenopausal women significance14 4-6 wk for • Well tolerated: might cause rash, • Improves time to effect with laser lower face) burning, or tingling therapy (up to 95% successful)12 • EE with • Generalized hirsutism, for • Improvement noted at 3 mo; 1 tablet, orally, once drospirenone women not seeking fertility maximum effect at 9-12 mo daily ($17-$23) (Yasmin, Yaz) • All OCPs can help owing to • Yasmin: FGS 65%-70% lower at • EE with desogestrel estrogen’s effect on SHBG 6 mo and 80% lower at 12 mo18,19 (Marvelon, • Risk of VTE, although small, • Marvelon: FGS 40% lower at 6 mo Ortho-Cept, Linessa) increases with age (especially and 35% lower at 12 mo18 • EE with > 39 y) and possibly choice • Tri-Cyclen: no specific evidence norgestimate of OCP CPs O (Tri-Cyclen, -baseline risk: about 5/10 000 Tri-Cyclen LO, Cyclen) -with OCPs: 8-9/10 000 (up to • See full RxFiles 14/10 000) chart15 for other -possible increased risk with low-androgen OCP Yasmin, Yaz16,17 options • EE with • Mild hirsutism, severe acne • Diane-35: FGS 55% lower at 6 mo EE 35 µg with CPA cyproterone* • Risk of VTE, though small, might and 80% lower at 12 mo17,19 2 mg ($29)
Recommended publications
  • Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
    Journal of Clinical Medicine Review Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals Carlotta Cocchetti 1, Jiska Ristori 1, Alessia Romani 1, Mario Maggi 2 and Alessandra Daphne Fisher 1,* 1 Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University Hospital, 50139 Florence, Italy; [email protected] (C.C); jiska.ristori@unifi.it (J.R.); [email protected] (A.R.) 2 Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, 50139 Florence, Italy; [email protected]fi.it * Correspondence: fi[email protected] Received: 16 April 2020; Accepted: 18 May 2020; Published: 26 May 2020 Abstract: Introduction: To date no standardized hormonal treatment protocols for non-binary transgender individuals have been described in the literature and there is a lack of data regarding their efficacy and safety. Objectives: To suggest possible treatment strategies for non-binary transgender individuals with non-standardized requests and to emphasize the importance of a personalized clinical approach. Methods: A narrative review of pertinent literature on gender-affirming hormonal treatment in transgender persons was performed using PubMed. Results: New hormonal treatment regimens outside those reported in current guidelines should be considered for non-binary transgender individuals, in order to improve psychological well-being and quality of life. In the present review we suggested the use of hormonal and non-hormonal compounds, which—based on their mechanism of action—could be used in these cases depending on clients’ requests. Conclusion: Requests for an individualized hormonal treatment in non-binary transgender individuals represent a future challenge for professionals managing transgender health care. For each case, clinicians should balance the benefits and risks of a personalized non-standardized treatment, actively involving the person in decisions regarding hormonal treatment.
    [Show full text]
  • Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning
    Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy using Machine Learning Kate Wang et al. Supplemental Table S1. Drugs selected by Pharmacophore-based, ML-based and DL- based search in the FDA-approved drugs database Pharmacophore WEKA TF 1-Palmitoyl-2-oleoyl-sn-glycero-3- 5-O-phosphono-alpha-D- (phospho-rac-(1-glycerol)) ribofuranosyl diphosphate Acarbose Amikacin Acetylcarnitine Acetarsol Arbutamine Acetylcholine Adenosine Aldehydo-N-Acetyl-D- Benserazide Acyclovir Glucosamine Bisoprolol Adefovir dipivoxil Alendronic acid Brivudine Alfentanil Alginic acid Cefamandole Alitretinoin alpha-Arbutin Cefdinir Azithromycin Amikacin Cefixime Balsalazide Amiloride Cefonicid Bethanechol Arbutin Ceforanide Bicalutamide Ascorbic acid calcium salt Cefotetan Calcium glubionate Auranofin Ceftibuten Cangrelor Azacitidine Ceftolozane Capecitabine Benserazide Cerivastatin Carbamoylcholine Besifloxacin Chlortetracycline Carisoprodol beta-L-fructofuranose Cilastatin Chlorobutanol Bictegravir Citicoline Cidofovir Bismuth subgallate Cladribine Clodronic acid Bleomycin Clarithromycin Colistimethate Bortezomib Clindamycin Cyclandelate Bromotheophylline Clofarabine Dexpanthenol Calcium threonate Cromoglicic acid Edoxudine Capecitabine Demeclocycline Elbasvir Capreomycin Diaminopropanol tetraacetic acid Erdosteine Carbidopa Diazolidinylurea Ethchlorvynol Carbocisteine Dibekacin Ethinamate Carboplatin Dinoprostone Famotidine Cefotetan Dipyridamole Fidaxomicin Chlormerodrin Doripenem Flavin adenine dinucleotide
    [Show full text]
  • Progestogens and Venous Thromboembolism Among Postmenopausal Women Using Hormone Therapy. Marianne Canonico, Geneviève Plu-Bureau, Pierre-Yves Scarabin
    Progestogens and venous thromboembolism among postmenopausal women using hormone therapy. Marianne Canonico, Geneviève Plu-Bureau, Pierre-Yves Scarabin To cite this version: Marianne Canonico, Geneviève Plu-Bureau, Pierre-Yves Scarabin. Progestogens and venous throm- boembolism among postmenopausal women using hormone therapy.. Maturitas, Elsevier, 2011, 70 (4), pp.354-60. 10.1016/j.maturitas.2011.10.002. inserm-01148705 HAL Id: inserm-01148705 https://www.hal.inserm.fr/inserm-01148705 Submitted on 5 May 2015 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Progestogens and VTE Finale version Progestogens and venous thromboembolism among postmenopausal women using hormone therapy Marianne Canonico1,2, Geneviève Plu-Bureau1,3 and Pierre-Yves Scarabin1,2 1 Centre for Research in Epidemiology and Population Health, U1018, Hormones and Cardiovascular Disease 2 University Paris-Sud, UMR-S 1018, Villejuif, France 3 University Paris Descartes and Hôtel-Dieu Hospital, Paris, France Adresse: 16 av. Paul Vaillant Couturier 94807 Villejuif Cedex Tel: +33 1 45 59 51 66 Fax: +33 1 45 59 51 70 Corresponding author: Marianne Canonico ([email protected]) 1/21 Progestogens and VTE Finale version Abstract Hormone therapy (HT) is the most effective treatment for correcting menopausal symptoms after menopause.
    [Show full text]
  • New Drugs Are Not Enough‑Drug Repositioning in Oncology: an Update
    INTERNATIONAL JOURNAL OF ONCOLOGY 56: 651-684, 2020 New drugs are not enough‑drug repositioning in oncology: An update ROMINA GABRIELA ARMANDO, DIEGO LUIS MENGUAL GÓMEZ and DANIEL EDUARDO GOMEZ Laboratory of Molecular Oncology, Science and Technology Department, National University of Quilmes, Bernal B1876, Argentina Received August 15, 2019; Accepted December 16, 2019 DOI: 10.3892/ijo.2020.4966 Abstract. Drug repositioning refers to the concept of discov- 17. Lithium ering novel clinical benefits of drugs that are already known 18. Metformin for use treating other diseases. The advantages of this are that 19. Niclosamide several important drug characteristics are already established 20. Nitroxoline (including efficacy, pharmacokinetics, pharmacodynamics and 21. Nonsteroidal anti‑inflammatory drugs toxicity), making the process of research for a putative drug 22. Phosphodiesterase-5 inhibitors quicker and less costly. Drug repositioning in oncology has 23. Pimozide received extensive focus. The present review summarizes the 24. Propranolol most prominent examples of drug repositioning for the treat- 25. Riluzole ment of cancer, taking into consideration their primary use, 26. Statins proposed anticancer mechanisms and current development 27. Thalidomide status. 28. Valproic acid 29. Verapamil 30. Zidovudine Contents 31. Concluding remarks 1. Introduction 2. Artesunate 1. Introduction 3. Auranofin 4. Benzimidazole derivatives In previous decades, a considerable amount of work has been 5. Chloroquine conducted in search of novel oncological therapies; however, 6. Chlorpromazine cancer remains one of the leading causes of death globally. 7. Clomipramine The creation of novel drugs requires large volumes of capital, 8. Desmopressin alongside extensive experimentation and testing, comprising 9. Digoxin the pioneer identification of identifiable targets and corrobora- 10.
    [Show full text]
  • Steroid Abuse by School Age Children
    epartment .D of .S Ju U s t ic U.S. Department of Justice e . n o i Drug Enforcement Administration t a r t is D in Office of Diversion Control r m ug d E t A nforcemen www.dea.gov www.DEAdiversion.usdoj.gov epartment .D of .S Ju U s t ic e . n o i t a r t is D in r m ug d E t A nforcemen Office of Diversion Control www.dea.gov STEROID ABUSE BY SCHOOL AGE CHILDREN nce viewed as a problem strictly associated with body builders, Ofitness “buffs,” and professional athletes, abuse of anabolic steroids by school age children has significantly increased over the past decade. The National Institute on Drug Abuse (NIDA) estimates that more than a half million 8th and 10th grade students are now using these dangerous drugs, and increasing numbers of high school seniors do not believe steroids are risky. Students are acquiring and taking anabolic steroids without any knowledge of the dangers associated with steroid abuse. The short- term adverse physical effects of anabolic steroid abuse are fairly well known. However, the long-term adverse physical effects of anabolic steroid abuse have not been studied, and as such, are not known. In addition, this type of abuse may result in harmful side-effects as well as serious injury and death. The abuser in most cases is unaware of these hidden dangers. Presented as a public service by: This guide will help you understand why steroids are being misused, Drug Enforcement Administration and how you can provide counseling and implement procedures to Office of Diversion Control educate our youth about the dangers of these drugs.
    [Show full text]
  • Role of Androgens, Progestins and Tibolone in the Treatment of Menopausal Symptoms: a Review of the Clinical Evidence
    REVIEW Role of androgens, progestins and tibolone in the treatment of menopausal symptoms: a review of the clinical evidence Maria Garefalakis Abstract: Estrogen-containing hormone therapy (HT) is the most widely prescribed and well- Martha Hickey established treatment for menopausal symptoms. High quality evidence confi rms that estrogen effectively treats hot fl ushes, night sweats and vaginal dryness. Progestins are combined with School of Women’s and Infants’ Health The University of Western Australia, estrogen to prevent endometrial hyperplasia and are sometimes used alone for hot fl ushes, King Edward Memorial Hospital, but are less effective than estrogen for this purpose. Data are confl icting regarding the role of Subiaco, Western Australia, Australia androgens for improving libido and well-being. The synthetic steroid tibolone is widely used in Europe and Australasia and effectively treats hot fl ushes and vaginal dryness. Tibolone may improve libido more effectively than estrogen containing HT in some women. We summarize the data from studies addressing the effi cacy, benefi ts, and risks of androgens, progestins and tibolone in the treatment of menopausal symptoms. Keywords: androgens, testosterone, progestins, tibolone, menopause, therapeutic Introduction Therapeutic estrogens include conjugated equine estrogens, synthetically derived piperazine estrone sulphate, estriol, dienoestrol, micronized estradiol and estradiol valerate. Estradiol may also be given transdermally as a patch or gel, as a slow release percutaneous implant, and more recently as an intranasal spray. Intravaginal estrogens include topical estradiol in the form of a ring or pessary, estriol in pessary or cream form, dienoestrol and conjugated estrogens in the form of creams. In some countries there is increasing prescribing of a combination of estradiol, estrone, and estriol as buccal lozenges or ‘troches’, which are formulated by private compounding pharmacists.
    [Show full text]
  • WHO Model List (Revised April 2003) Explanatory Notes
    13th edition (April 2003) Essential Medicines WHO Model List (revised April 2003) Explanatory Notes The core list presents a list of minimum medicine needs for a basic health care system, listing the most efficacious, safe and cost-effective medicines for priority conditions. Priority conditions are selected on the basis of current and estimated future public health relevance, and potential for safe and cost-effective treatment. The complementary list presents essential medicines for priority diseases, for which specialized diagnostic or monitoring facilities, and/or specialist medical care, and/or specialist training are needed. In case of doubt medicines may also be listed as complementary on the basis of consistent higher costs or less attractive cost-effectiveness in a variety of settings. When the strength of a drug is specified in terms of a selected salt or ester, this is mentioned in brackets; when it refers to the active moiety, the name of the salt or ester in brackets is preceded by the word "as". The square box symbol (? ) is primarily intended to indicate similar clinical performance within a pharmacological class. The listed medicine should be the example of the class for which there is the best evidence for effectiveness and safety. In some cases, this may be the first medicine that is licensed for marketing; in other instances, subsequently licensed compounds may be safer or more effective. Where there is no difference in terms of efficacy and safety data, the listed medicine should be the one that is generally available at the lowest price, based on international drug price information sources.
    [Show full text]
  • Hirsutism and Polycystic Ovary Syndrome (PCOS)
    Hirsutism and Polycystic Ovary Syndrome (PCOS) A Guide for Patients PATIENT INFORMATION SERIES Published by the American Society for Reproductive Medicine under the direction of the Patient Education Committee and the Publications Committee. No portion herein may be reproduced in any form without written permission. This booklet is in no way intended to replace, dictate or fully define evaluation and treatment by a qualified physician. It is intended solely as an aid for patients seeking general information on issues in reproductive medicine. Copyright © 2016 by the American Society for Reproductive Medicine AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE Hirsutism and Polycystic Ovary Syndrome (PCOS) A Guide for Patients Revised 2016 A glossary of italicized words is located at the end of this booklet. INTRODUCTION Hirsutism is the excessive growth of facial or body hair on women. Hirsutism can be seen as coarse, dark hair that may appear on the face, chest, abdomen, back, upper arms, or upper legs. Hirsutism is a symptom of medical disorders associated with the hormones called androgens. Polycystic ovary syndrome (PCOS), in which the ovaries produce excessive amounts of androgens, is the most common cause of hirsutism and may affect up to 10% of women. Hirsutism is very common and often improves with medical management. Prompt medical attention is important because delaying treatment makes the treatment more difficult and may have long-term health consequences. OVERVIEW OF NORMAL HAIR GROWTH Understanding the process of normal hair growth will help you understand hirsutism. Each hair grows from a follicle deep in your skin. As long as these follicles are not completely destroyed, hair will continue to grow even if the shaft, which is the part of the hair that appears above the skin, is plucked or removed.
    [Show full text]
  • Interactions with Protease Inhibitors Charts Revised February 2018
    www.hiv-druginteractions.org Interactions with Protease Inhibitors Charts revised February 2018. Full information available at www.hiv-druginteractions.org Page 1 of 4 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. ATV Cobi DRV FPV IDV LPV RTV SQV TPV ATV Cobi DRV FPV IDV LPV RTV SQV TPV Anaesthetics & Muscle Relaxants Antibacterials (continued) Alcuronium Ertapenem Bupivacaine Erythromycin Cisatracurium Ethambutol Desflurane Ethionamide Dexmedetomidine Flucloxacillin Enflurane Gentamicin Ephedrine Imipenem/Cilastatin Halothane Isoniazid Isoflurane Kanamycin Ketamine Levofloxacin Linezolid Nitrous oxide Meropenem Propofol Metronidazole Rocuronium Moxifloxacin Sevoflurane Nitrofurantoin Sufentanil Ofloxacin Suxamethonium (succinylcholine) Para-aminosalicylic acid Tetracaine Penicillins Thiopental for distribution. for Pyrazinamide Tizanidine Rifabutin Vecuronium Rifampicin Analgesics Rifapentine Alfentanil Rifaximin Aspirin Spectinomycin Buprenorphine Streptomycin Celecoxib Sulfadiazine Codeine Telithromycin Tetracyclines
    [Show full text]
  • The Combined Cardiac Effect of the Anabolic Steroid, Nandrolone And
    ù1. v -¿. rlc) 77.- *n*hi.rnool oowol,ù*o ffi"/fu -lo *rn*(o fii'o fio¿o¿¿, /v&"ùún lonno **al cooaiæe';¿vfl"- oã. Benjamin D. Phillis, B.Sc. (Hons) Phatmacology Depattment of Clinical & Experimental Pharmacology Ftome Rd. , Medical School Noth Adelaide Univetsity ADEIAIDE SA 5OOO û.)r.'-*hr/7enveltîù Foremost, I would like to thank my two supervisors for the direction that they have given this ptojecr. To Rod, for his unfailing troubleshooting abiJity and to Jenny fot her advice and ability to add scientific rigour' Many thanks to Michael Adams for his technical assistance and especially fot performing the surgery for the ischaemia-reperfusion projects and for his willingness to work late nights and public holidays. Lastly I would like to thank my v¡ife for her extreme patience during the tumult of the last 5 years. Her love, suppoït, patience and undetstanding have been invaluable in this endeavout. Beniamin D. Phillis Octobet,2005 ADE,I-AIDE ii T*(¿t of Ao,t",tù DECI.ARATION I ACKNOWLEDGEMENTS il TABLE OF CONTENTS UI ABBREVIATIONS x ABSTRACT )ilr CÉIAPTER t-l Inttoduction 1-1 1.1 Background 1,-1, 1.2What ate anabolic stetoids? 7-1 1,3 General pharmacology of Anabolic steroids t-2 '1,-2 1.3.1 Genomic effects of anabolic steroids 1.3.2 Non-genomic effects of anabolic steroids 1-3 1.4 Clinical use of AS 1.-4 1.5 Patterns of AS abuse 1.-4 1.5.1 Steroid abuse by athletes 1.-+ 1.5.2 Stetoid abuse by sedentary teenagers r-6 1.5.3 Prevalence of abuse 1-6 1.5.4 Abuse ptevalence in Australia 1.-9 1.6 Cardiotoxicity of anabolic steroids r-9 1.6.1 Reduced cotonary flow 1.-1.1, 1,.6.2 Dtect myocatdial eff ects 1-1 5 1.6.3 Hypertension 1-21 1.7 Difficulties associated with anabolic steroid research 1.-24 1-25 1.8 The polydrug abuse Phenomenon 1.9 The pharmacology of cocaine 1-26 1.10 Pteparations 1-28 1-29 1.11 Metabolism lll 1-30 1.
    [Show full text]
  • CLINICAL REVIEW Management of Hirsutism
    For the full versions of these articles see bmj.com CLINICAL REVIEW Management of hirsutism Olympia Koulouri, Gerard S Conway Department of Endocrinology, Hirsutism is the presence of excess hair growth in that secrete androgens are rare and tend to cause severe University College London women, and the term usually refers to excessive hirsutism. Adrenal tumours usually co-secrete cortisol Hospitals, London NW1 2PQ growth of terminal hair in an androgen dependent dis- and the clinical picture is that of Cushing’s syndrome. Correspondence to: G S Conway [email protected] tribution. Although it is often thought to be a cosmetic At the time of the menopause, hair growth is pro- problem, unwanted hair growth adversely affects psy- moted by a fall in the production of ovarian oestradiol Cite this as: BMJ 2009;338:b847 chological wellbeing.1 It can have a similar effect on but relatively well maintained testosterone production. doi:10.1136/bmj.b847 quality of life scores to that of asthma, epilepsy, and In some instances, rising concentrations of luteinising diabetes,2 and effective treatments reverse these hormone lead to stromal hyperplasia, high testoster- adverse scores.3 one concentrations, and severe menopausal hirsutism. Several new treatments have emerged in recent years, including the wider availability of laser depilation, topi- What aspects of the history and examination are cal suppressors of hair growth (eflornithene), and a pro- important? gestogen with antiandrogenic properties (drospirenone). For research purposes, hair growth can be measured In this review, we assess the evidence base for new treat- using a scoring system established by Ferriman and ments in the context of established treatments, although Gallwey.5 In clinical practice, subjective assessment is the worldwide availability of these preparations varies usually adequate, although personal perception of greatly.
    [Show full text]
  • Spironolactone for Adult Female Acne
    ® PPracticalEDIATRIC DERMATOLOGY Pearls From the Cutis Board Spironolactone for Adult Female Acne Many cases of acne are hormonal in nature, meaning that they occur in adolescent girls and women and are aggravated by hormonal fluctuations such as those that occur during the menstrual cycle or in the setting of underlying hormonal imbalances as seen in polycystic ovary syndrome. For these patients, antihormonal therapy such as spironolactone is a valid and efficacious option. Herein, initiation and utilization of this medication is reviewed. Adam J. Friedman, MD copy What should you do during the first Evaluation of these women with acne for the visit for a patient you may start possibility of hormonal imbalance may be necessary, on spironolactone? with the 2 most common causes of hyperandrogen- Some women will come in asking about spironolac- ismnot being polycystic ovary syndrome and congeni- tone for acne, so it is important to identify potential tal adrenal hyperplasia. The presence of alopecia, candidates for antihormonal therapy: hirsutism, acanthosis nigricans, or other signs of • Women with acne flares that cycle androgen excess, in combination with dysmenor- with menstruation Dorhea or amenorrhea, may be an indication that the • Women with adult-onset acne or persistent- patient has an underlying medical condition that recurrent acne past teenaged years, even needs to be addressed. Blood tests including testos- in the absence of clinical or laboratory signs terone, dehydroepiandrosterone, follicle-stimulating of hyperandrogenism hormone, and luteinizing hormone would be appro- • Women on oral contraceptives (OCs) who priate screening tests and should be performed dur- exhibit moderate to severe acne, especially ing the menstrual period or week prior; the patient with a hormonal patternCUTIS clinically should not be on an OC or have been on one within • Women not responding to conventional ther- the last 6 weeks of testing.
    [Show full text]